Economic evaluation of pemetrexed versus erlotinib as second-line treatment of patients with advanced/metastatic non-small cell lung cancer in Greece: A cost minimization analysis

Lung Cancer: Targets and Therapy

Volumn 3, Issue , 2012, Pages 43-51

  Fragoulakis, V F ^a   Pallis, A G ^c   Kaitelidou, D K ^b   Maniadakis, N M ^a   Georgoulias, V G ^c  

^a NATIONAL SCHOOL OF PUBLIC HEALTH   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

Economic evaluation; Erlotinib; Lung cancer; Pemetrexed

Indexed keywords

ERLOTINIB; PEMETREXED;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; COST MINIMIZATION ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG RESPONSE; ECONOMIC EVALUATION; FEMALE; FOLLOW UP; GREECE; HEALTH CARE UTILIZATION; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; SURVIVAL RATE;

EID: 84874771358     PISSN: None     EISSN: 11792728     Source Type: Journal    
DOI: 10.2147/LCTT.S33608     Document Type: Article

References (37)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90.
2. NSCLC Meta-Analyses Collaborative Group. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol. 2008;26(28): 4617-4625.
3. Delbaldo C, Michiels S, Syz N, Soria JC, Le CT, Pignon JP. Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis. JAMA. 2004; 292(4):470-484.
4. Azzoli CG, Baker S Jr, Temin S, et al. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol. 2009;27(36): 6251-6266.
5. Shepherd FA, Rodrigues PJ, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353(2): 123-132.
6. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. Journal of Clinical Oncology. 2004;22(9):1589-1597.
7. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. Journal of Clinical Oncology. 2000;18(10):2095-2103.
8. Vamvakas L, Agelaki S, Kentepozidis N, et al. Pemetrexed (MTA) compared with erlotinib (ERL) in pretreated patients with advanced non-small cell lung cancer (NSCLC): Results of a randomized phase III Hellenic Oncology Research Group trial. J Clin Oncol. 2010;28(7s):Abstr 7519.
9. Scagliotti GV, Parikh P, von PJ, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapynaive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26(21):3543-3551.
10. Ramsey S, Willke R, Briggs A, et al. Good research practices for costeffectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report. Value Health. 2005;8(5):521-533.
11. Gold M. Panel on cost-effectiveness in health and medicine. Med Care. 1996;34(Suppl 12):DS197-DS199.
12. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA. 1996;276(15):1253-1258.
13. Greek Ministry of Health. Drug price bulletin. http://www.yyka.gov. gr/. Accessed at July 24, 2011.
14. O'Hagan A, Stevens JW. On estimators of medical costs with censored data. J Health Econ. 2004;23(3):615-625.
15. Doshi JA, Glick HA, Polsky D. Analyses of cost data in economic evaluations conducted alongside randomized controlled trials. Value Health. 2006;9(5):334-340.
16. Bang H, Tsiatis AA. Estimating medical costs with censored data. Biometrika. 2000;87(2):329-343.
17. Lin DY, Feuer EJ, Etzioni R, Wax Y. Estimating medical costs from incomplete follow-up data. Biometrics. 1997;53:113-128.
18. Zhao H, Tian L. On estimating medical cost and incremental costeffectiveness ratios with censored data. Biometrics. 2001;57(4): 1002-1008.
19. Carides GW, Heyse JF, Iglewicz B. A regression-based method for estimating mean treatment cost in the presence of right-censoring. Biostatistics. 2000;1(3):299-313.
20. Maniadakis N, Fragoulakis V, Pallis AG, Simou E, Georgoulias V. Economic evaluation of docetaxel-gemcitabine versus vinorelbinecisplatin combination as front-line treatment of patients with advanced/ metastatic non-small-cell lung cancer in Greece: a cost-minimization analysis. Ann Oncol. 2010;21(7):1462-1467.
21. Raikou M, McGuire A. Estimating medical care costs under conditions of censoring. J Health Econ. 2004;23(3):443-470.
22. Sullivan R, Peppercorn J, Sikora K, et al. Delivering affordable cancer care in high-income countries. Lancet Oncol. 2011;12(10):933-980.
23. Zhao H, Bang H, Wang H, Pfeifer PE. On the equivalence of some medical cost estimators with censored data. Stat Med. 2007;26(24): 4520-4530.
24. Lin DY. Linear regression analysis of censored medical costs. Biostatistics. 2000;1(1):35-47.
25. Lin DY. Proportional means regression for censored medical costs. Biometrics. 2000;56(3):775-778.
26. Lin DY. Regression analysis of incomplete medical cost data. Stat Med. 2003;22(7):1181-1200.
27. Kim ES, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet. 2008;372(9652):1809-1818.
28. Carlson JJ, Reyes C, Oestreicher N, Lubeck D, Ramsey SD, Veenstra DL. Comparative clinical and economic outcomes of treatments for refractory non-small cell lung cancer (NSCLC). Lung Cancer. 2008; 61(3):405-415.
29. Maniadakis N, Fragoulakis V, Pallis A, Prezerakos P, Georgoulias V. Economic evaluation of docetaxel/gemcitabine versus docetaxel as frontline treatment of patients with advanced/metastatic non-small cell lung cancer in Greece. Lung Cancer. 2007;58(2):275-281.
30. Holmes J, Dunlop D, Hemmett L, Sharplin P, Bose U. A cost-effectiveness analysis of docetaxel in the second-line treatment of non-small cell lung cancer. Pharmacoeconomics. 2004;22(9):581-589.
31. Lewis G, Peake M, Aultman R, et al. Cost-effectiveness of erlotinib versus docetaxel for second-line treatment of advanced non-small-cell lung cancer in the United Kingdom. J Int Med Res. 2010;38(1):9-21.
32. Lyseng-Williamson KA. Erlotinib: a pharmacoeconomic review of its use in advanced non-small cell lung cancer. Pharmacoeconomics. 2010;28(1):75-92.
33. Cromwell I, van der Hoek K, Melosky B, Peacock S. Erlotinib or docetaxel for second-line treatment of non-small cell lung cancer: a real-world cost-effectiveness analysis. J Thorac Oncol. 2011;6(12): 2097-2103.
34. Nadler E, Forsyth M, Satram-Hoang S, Reyes C. Costs and clinical outcomes among patients with second-line non-small cell lung cancer in the outpatient community setting. J Thorac Oncol. 2012;7(1): 212-218.
35. Araujo A, Parente B, Sotto-Mayor R, et al. An economic analysis of erlotinib, docetaxel, pemetrexed and best supportive care as second or third line treatment of non-small cell lung cancer. Rev Port Pneumol. 2008;14(6):803-827.
36. Scagliotti G, Hanna N, Fossella F, et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist. 2009;14(3):253-263.
37. Pallis AG, Fennell DA, Szutowicz E, Leighl NB, Greillier L, Dziadziuszko R. Biomarkers of clinical benefit for anti-epidermal growth factor receptor agents in patients with non-small-cell lung cancer. Br J Cancer. 2011;105(1):1-8.